Annika Sääf

Annika Sääf

Auto-generated profile, based on publicly available information

Annika Sääf

Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2025 in Science Advances
Verified
Journal Article
Open access
AAAinhoa Arina
Ainhoa Arina
EAEdwin Arauz
Edwin Arauz
EMElham Masoumi
Elham Masoumi
KWKarolina Weronika Warzecha
Karolina Weronika Warzecha
ASAnnika Sääf
Annika Sääf
AKAnthony A. Kossiakoff
Anthony A. Kossiakoff
Chimeric antigen receptor (CAR) T cell therapy has shown extraordinary results in treating hematological cancer but faces challenges like antigen loss, toxicity, and complex manufacturing. Universal and modular CAR constructs offer improved flexibility, safety, and cost-effectiveness over conventional CAR constructs. We present a CAR–fragment antibody binder (Fab) platform on the basis of an engineered protein G variant (GA1) and Fab scaffolds. Expression of GA1CAR on human CD8 + T cells leads to antigen recognition and T cell effector function that can be modulated according to the affinity of the CAR for the Fab and of the Fab for the target. GA1CAR T cells can recognize multiple Fab-antigen pairs on breast and ovarian cancer cell lines. Adoptively transferred GA1CAR T cells control tumors in breast cancer xenograft models, and their targeting can be quickly redirected using different Fabs. This versatile “plug-and-play” CAR T platform has potential for application in personalized therapy, preventing antigen loss variant escape, decreasing toxicity, and increasing access.